Evaluating Different Doses and Lengths of Dexamethasone Treatment for Acute Respiratory Distress Syndrome

What this Trial Is About

Researchers are evaluating corticosteroid therapy for Acute Respiratory Distress Syndrome ARDS, a condition marked by intense alveolar inflammation in its early phase. This phase 4 clinical trial aims to compare different corticosteroid doses and treatment durations to determine the best regimen for ARDS patients. The study also explores changes in inflammatory biomarkers to see if they can help guide steroid treatment choices. Participants will be randomly assigned to one of six groups in a 3x2 factorial design standard care without corticosteroids, low-dose dexamethasone for either 7 or 10 days, or medium-dose dexamethasone for either 7 or 10 days. Dexamethasone doses range from 0.1 to 0.2 mgkg with tapering over the treatment duration. The study compares no steroids, medium-low dose, and medium dose corticosteroids given either for a prolonged or short course. During the study, participants will be closely monitored with assessments including ventilator-free survival at 28 days, mortality rates up to 60 days, oxygenation improvement, and rates of infections and side effects like lymphocytopenia and hyperglycemia. This comprehensive monitoring will help evaluate the clinical outcomes and safety of different corticosteroid regimens. The trial duration extends until 2030, with primary outcome measured at 28 days.

Identifying an Optimal Corticosteroid Dosage Regimen for Acute Respiratory Distress Syndrome